MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of “Moderate Buy” from Analysts

MoonLake Immunotherapeutics (NASDAQ:MLTX) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $81.67.

MLTX has been the subject of a number of research analyst reports. Wedbush restated an “outperform” rating and issued a $80.00 target price (up from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday. The Goldman Sachs Group dropped their price target on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th. Royal Bank of Canada assumed coverage on shares of MoonLake Immunotherapeutics in a research note on Tuesday, March 18th. They set an “outperform” rating and a $67.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $66.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday.

MoonLake Immunotherapeutics Stock Down 0.1%

Shares of MoonLake Immunotherapeutics stock opened at $37.62 on Friday. The firm has a market cap of $2.41 billion, a P/E ratio of -29.16 and a beta of 1.31. The business has a 50-day moving average price of $38.40 and a 200 day moving average price of $44.73. MoonLake Immunotherapeutics has a fifty-two week low of $31.42 and a fifty-two week high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.13. During the same period last year, the company earned ($0.22) EPS. As a group, equities research analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Institutional Trading of MoonLake Immunotherapeutics

Hedge funds have recently modified their holdings of the company. FMR LLC boosted its stake in MoonLake Immunotherapeutics by 28.1% in the fourth quarter. FMR LLC now owns 6,341,391 shares of the company’s stock valued at $343,386,000 after acquiring an additional 1,391,167 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of MoonLake Immunotherapeutics by 12.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company’s stock worth $181,059,000 after acquiring an additional 363,394 shares during the period. Paradigm Biocapital Advisors LP raised its holdings in shares of MoonLake Immunotherapeutics by 90.3% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,772,211 shares of the company’s stock worth $95,965,000 after acquiring an additional 840,731 shares during the period. Westfield Capital Management Co. LP increased its stake in MoonLake Immunotherapeutics by 9.4% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,434,770 shares of the company’s stock valued at $56,056,000 after buying an additional 123,151 shares during the last quarter. Finally, Federated Hermes Inc. increased its stake in MoonLake Immunotherapeutics by 13.2% in the 4th quarter. Federated Hermes Inc. now owns 1,280,052 shares of the company’s stock valued at $69,315,000 after buying an additional 149,724 shares during the last quarter. Institutional investors and hedge funds own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.